NL-OMON20435
Recruiting
Not Applicable
ong term prospective observational cohort study of the safety and efficacy of certolizumab pegol in the daily clinical practice of rheumatoid arthritis with emphasis on the lipid profile.
Reade0 sites200 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- certolizumab pegolrheumatoid arthritissafetyefficacyIn het Nederlandscertolizumab pegolreumatoide artritisveiligheideffectiviteit
- Sponsor
- Reade
- Enrollment
- 200
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
/A
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Patients with rheumatoid arthritis in whom certolizumab pegol treatment is started;
- •2\. Written informed consent.
Exclusion Criteria
- •None, except for the contraindications against certolizumab pegol treatment.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 4
ong term prospective observational cohort study of the safety and efficacy of golimumab in the daily clinical practice of rheumatoid arthritis with emphasis on the lipid profileinflammatory rheumatic disease1000381610023213NL-OMON36406Jan van Breemen Instituut200
Recruiting
Phase 4
ong term prospective observational cohort study of the safety and efficacy of certolizumab pegol in the daily clinical practice of rheumatoid arthritis with emphasis on the lipid profileinflammatory rheumatic disease1000381610023213NL-OMON36770Jan van Breemen Instituut200
Recruiting
Phase 4
ong term prospective observational cohort study on the safety and efficacy of abatacept subcutaneus in the daily clinical practice of rheumatoid arthritisInflammatory rheumatic disease10023213NL-OMON39013Jan van Breemen Instituut100
Completed
Not Applicable
ong term, prospective, observational cohort study evaluating the safety profile in patients with highly active relapsing multiple sclerosis (RMS) newly started on oral cladribineG35.9DRKS00015267Merck KGaA1,115
Not yet recruiting
Not Applicable
Prospective observational cohort study on the correlation of microbiome diversity and oncological outcome in immune checkpoint inhibitor therapyC00-C97Malignant neoplasmsDRKS00030723Rheinische Friedrich-Wilhelms-Universität Bonn100